Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients

NCT01641458 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

OTHER: 5FU and capecitabine (Xeloda®) dosing based on DPYD genotype
OTHER: Therapeutic drug monitoring of 5FU

Sponsor

Cantonal Hospital of St. Gallen

Collaborators

[object Object]